pretomanid: Clinical Trials

12 trials of pretomanid, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 recruiting, 2 unknown, 1 active not recruiting. 12 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Completed 6, Recruiting 3, Unknown 2, Active not recruiting 1
Phase 26Completed 3, Active not recruiting 1, Recruiting 1, Unknown 1

Follow pretomanid: new trials by email Literature Review of pretomanid trials Research Report on pretomanid

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
Bedaquiline, Quabodepistat, Pretomanid - Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
Phase 3RecruitingOtsuka Pharmaceutical Development & Commercialization, Inc.5322025-10-162026-10-26
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
Bedaquiline, Linezolid, Pretomanid - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Phase 2 / Phase 3RecruitingUniversity of California, San Francisco4002025-10-032026-09-02
A PAN-USR TB Multi-Center Trial
Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis
Phase 3RecruitingShenzhen Third People's Hospital6102025-06-182025-12-01
A Pan-TB Regimen Targeting Host and Microbe
Sutezolid, N-acetyl cysteine, Pretomanid - Tuberculosis
Phase 2 / Phase 3Active not recruitingThe Aurum Institute NPC3522023-07-282025-05-28
Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India
Linezolid, Bedaquiline, Pretomanid - Pre-Extensively Drug-Resistant Pulmonary TB, Treatment Intolerant Multidrug-Resistant Pulmonary TB
Phase 3UnknownTuberculosis Research Centre, India4002021-10-072024-01-03
Economic Evaluation of New MDR TB Regimens
Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3CompletedMedecins Sans Frontieres, Netherlands732020-10-202024-04-22
PRACTECAL-PKPD Sub Study
Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3UnknownMedecins Sans Frontieres, Netherlands2402019-08-062021-05-14
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
Pretomanid, Bedaquiline, Moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Phase 2 / Phase 3CompletedGlobal Alliance for TB Drug Development4552018-07-302026-08-27
Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
Pretomanid, Linezolid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Phase 3CompletedGlobal Alliance for TB Drug Development1812017-11-212023-06-29
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
Bedaquiline, Pretomanid, Moxifloxacin - Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3CompletedMedecins Sans Frontieres, Netherlands5522017-01-012024-05-01
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
Bedaquiline, PA-824, Linezolid - Pulmonary Tuberculosis
Phase 3CompletedGlobal Alliance for TB Drug Development1092015-03-012025-09-08
Shortening Treatment by Advancing Novel Drugs
Moxifloxacin, PA-824, Pyrazinamide - Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant
Phase 3CompletedGlobal Alliance for TB Drug Development2842015-02-012019-03-26

Conditions studied

Tuberculosis, Multidrug-Resistant (9)  ·  Tuberculosis, Pulmonary (8)  ·  Tuberculosis (6)  ·  Extensively Drug-Resistant Tuberculosis (5)

Sponsors

Global Alliance for TB Drug Development (4)  ·  Medecins Sans Frontieres, Netherlands (3)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (1)  ·  Shenzhen Third People's Hospital (1)  ·  The Aurum Institute NPC (1)  ·  Tuberculosis Research Centre, India (1)  ·  University of California, San Francisco (1)

Countries

South Africa (9)  ·  Georgia (4)  ·  Belarus (3)  ·  Philippines (3)  ·  Tanzania (3)  ·  Uganda (3)  ·  China (2)  ·  India (2)  ·  Malaysia (2)  ·  Moldova (2)  ·  Peru (2)  ·  Russia (2)  ·  Uzbekistan (2)  ·  Brazil (1)  ·  Indonesia (1)

Top investigators

Bern Nyang'wa, MB BS, MPH (1)  ·  Bern-Thomas Nyang'wa, MD (1)  ·  Francesca Conradie (1)  ·  Francesca Conradie, MD (1)  ·  Morounfolu Olugbosi, MD (1)  ·  Morounfolu Olugbosi, MD MSc (1)  ·  Padmapriyadarsini Chandrasekharan (1)  ·  Professor Robert Wallis, MD (1)  ·  Sedona Sweeny (1)  ·  Simbarashe G Takuva, MD, MSc. (1)  ·  Stephen H Gillespie, MD (1)

Results publications

PMID 36053506, PMID 36546625, PMID 37980911, PMID 26038418, PMID 26104205, PMID 32130813, PMID 34489274, PMID 34604901, PMID 35698158, PMID 36038181, PMID 36804834, PMID 36808186, PMID 37567554, PMID 38768617, PMID 38842323, PMID 41749341, PMID 41917253, PMID 42270675, PMID 42429813